News Sentiment

ENTA sentiment intelligence

Enanta Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 13.70 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-9.3% over one week, +15.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -9.3% Price reacting lower
Trend fit Trend inactive 15.1% over four weeks
Fair value 23.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 46
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 15
Market source 9
Business Wire 5
simplywall.st 5
Moomoo 3
Investing.com 3
Ad Hoc News 2
Investing.com Canada 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 18
Regulatory and legal 7
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
TradingView Direct company coverage

Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA

The article provides financial data for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), specifically focusing on its enterprise value to EBITDA forward. It indicates the stock market status as closed with no trades. The document highlights the data sources and copyright information

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 00:13
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – DUS:9EP

The article focuses on the enterprise value to EBIT forward for Enanta Pharmaceuticals, Inc. (DUS:9EP) as listed on the Dusseldorf Stock Exchange. It provides a financial overview, though no specific values are present, and highlights the company's listing within the Health Techn

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 15:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – SWB:9EP

This page on TradingView provides financial information for Enanta Pharmaceuticals, Inc. (SWB:9EP), focusing on its enterprise value to forward EBITDA. The content is primarily an outline for financial data and analysis tools available on the platform, without detailed numerical

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 13:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – DUS:9EP

This page provides financial data, specifically the Enterprise Value to EBITDA forward, for Enanta Pharmaceuticals, Inc. (9EP) traded on the Dusseldorf Stock Exchange. It appears to be a financial data snippet from TradingView, offering a quick overview without detailed analysis

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 11:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – GETTEX:9EP

This page from TradingView displays financial information for Enanta Pharmaceuticals, Inc. (GETTEX:9EP), specifically focusing on its Enterprise Value to EBITDA forward metric. The content indicates that the market is currently closed, and no trades have occurred for this stock.

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 12:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – GETTEX:9EP

This page provides financial data for Enanta Pharmaceuticals, Inc. (GETTEX:9EP), specifically focusing on its enterprise value to EBIT forward. The content is hosted on TradingView, a platform offering various financial tools and market data, and includes legal disclaimers about

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 10:42
Source
TradingView
Investing.com Canada Direct company coverage

Form 424B5 Enanta Pharmaceuticals Inc For: 2 July By Investing.com

This article announces the filing of Form 424B5 for Enanta Pharmaceuticals Inc. on July 2nd. It provides basic information about the filing and includes irrelevant market data and news headlines, typical of an Investing.com article.

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 00:12
Source
Investing.com Canada
TradingView Direct company coverage

Price to sales forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA

This page on TradingView.com focuses on the "Price to sales forward" metric for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It provides financial data and an overview of the company's valuation, indicating information about the market performance and financial health of Enanta P

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 15:40
Source
TradingView
www.marketscreener.com Direct company coverage

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark

Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) has been added to the Russell Small Cap Comp Growth Benchmark, as well as the Russell 2500 Growth and Russell 2000 Growth Benchmarks. This inclusion indicates recognition of the company's growth potential within the small-cap market.

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 21:10
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark

Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) has been added to the Russell 3000E Growth Benchmark. The clinical-stage biotechnology company, focused on virology and immunology, saw its stock rise by 4.09% to 14.00 USD. This inclusion highlights the company's growth potential and

Tone
Positive 67/100
Event
Market update
Published
29 Jun 2026 03:40
Source
www.marketscreener.com
Moomoo Direct company coverage

Enanta Pharmaceuticals | SCHEDULE 13G/A: Others

This article indicates that a SCHEDULE 13G/A filing related to Enanta Pharmaceuticals (ENTA) has been submitted into the public record. The filing is categorized under "Others," suggesting a beneficial ownership report from a passive investor or another type of filer.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 23:38
Source
Moomoo
TradingView Direct company coverage

Enanta Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ENTA)

This article provides financial actuals and estimates for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), including stock price performance, analyst forecasts, earnings, revenue, and market capitalization. It highlights the company's historical stock prices, volatility, and upcoming

Tone
Positive 65/100
Event
Earnings
Published
26 Jun 2026 09:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP

This article focuses on the enterprise value to revenue forward for Enanta Pharmaceuticals, Inc. (TRADEGATE:9EP). It lists the company's trading information on the Tradegate Exchange, indicating that the market is currently closed with no trades. The piece is primarily a financia

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 09:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA

This article provides the "Price to book forward" for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It is a finance-related snippet from TradingView, indicating a focus on financial metrics for the company. The content itself is minimalist, primarily showcasing the title and conte

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 09:39
Source
TradingView
TradingView Direct company coverage

Enanta Pharmaceuticals, Inc. Actuals & Estimates (FWB:9EP)

This article provides an overview of Enanta Pharmaceuticals, Inc. (FWB:9EP) financials, analyst forecasts, and historical stock performance. It includes details on past earnings, revenue, EBITDA, and provides predictions for future financial results, noting that the company does

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 04:10
Source
TradingView
TradingView Direct company coverage

ENTA Forecast — Price Target — Prediction for 2027

This article provides a forecast for Enanta Pharmaceuticals, Inc. (ENTA) stock, including analyst price targets, historical performance, and key financial data. Eight analysts have provided 1-year price forecasts, with a maximum estimate of $32.00 and a minimum of $14.00. The com

Tone
Positive 66/100
Event
Analyst action
Published
25 Jun 2026 22:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA

This article displays the "Price to earnings forward" metric for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It presents financial data for the company, accessible through TradingView, and includes general market and company information. The content primarily focuses on the stoc

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 20:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP

This article provides financial information for Enanta Pharmaceuticals, Inc. (TRADEGATE:9EP), specifically focusing on its price to book forward value. The data is available through TradingView, which aggregates market and reference data from various providers.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 17:09
Source
TradingView
Market source Direct company coverage

Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?

Enanta Pharmaceuticals (ENTA) saw its shares rally 5.2% after its partner, AbbVie, received European Commission approval for Maviret to treat acute hepatitis C. Enanta receives royalties from Maviret's sales. Despite the immediate bump, the stock's future strength is uncertain as

Tone
Positive 67/100
Event
Regulatory and legal
Published
24 Jun 2026 13:39
Source
Market source
The Pharmaletter Direct company coverage

EC approves label expansion for Enanta’s Maviret in acute HCV infection

The European Commission (EC) has approved Maviret (glecaprevir/pibrentasvir) for treating acute hepatitis C virus (HCV) infection in adults and children aged three years and older. This approval makes Maviret the only treatment available in the EU for both acute and chronic HCV i

Tone
Positive 72/100
Event
Regulatory and legal
Published
24 Jun 2026 10:39
Source
The Pharmaletter
Investing.com Direct company coverage

Form 8K Enanta Pharmaceuticals Inc For: 23 June

This article reports on an SEC Form 8K filing by Enanta Pharmaceuticals Inc for June 23. It states that the information provided is not necessarily real-time or accurate and advises readers about the high risks associated with trading financial instruments and cryptocurrencies. T

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 04:39
Source
Investing.com